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1. Introduction
In Canada, ovarian cancer affects 2600 women and 1750 women die annually from this dis‐
ease.[1] The case fatality rate for ovarian cancer is quite high at 0.67 because women usually
present with wide-spread disease. Symptoms of ovarian cancer are non-specific, and there is
no effective screening test which identifies ovarian cancer early, when the cure rate is high‐
est.[2] When patients present with advanced disease, long term survival is elusive and the
goals of care focus on increasing duration of survival and improving quality of life by man‐
aging symptoms of disease.
Ovarian cancer is usually managed with a combination of surgery and chemotherapy. The
role of surgery is to make a histologic diagnosis, determine the extent of disease spread
(staging) and remove as much disease as possible (debulking). The role of chemotherapy is
to reverse the vascular permeability of tumour capillaries, thereby decreasing the presence
of ascites and pleural effusions, and to cause cellular apoptosis of tumour cells, resulting in
disease regression.
Evaluation  of  the  patterns  of  care  provided to  patients  with  ovarian  cancer  in  Ontario,
Canada demonstrated a variety of specialists are involved in the delivery of surgery in‐
cluding gynaecologists, general surgeons and gynaecologic oncologists.[3] The delivery of
chemotherapy can  be  provided by  medical  or  gynaecologic  oncologists.  Surgery  and/or
chemotherapy can be delivered in low, medium or high volume centres in rural or urban
settings and by teaching or non-teaching faculty.[3] This paper addresses the question of
whether  the  context  in  which a  woman receives  care  for  her  ovarian cancer  affects  her
outcome.
© 2013 Elit and Reade; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. Quality of care
The focus of this chapter falls within the rubric of quality of care. The Institute of Medicine
has defined quality of care as “the degree to which health services for individuals and popu‐
lations increase the likelihood of desired health outcomes and are consistent with current
professional knowledge”.[4] Good quality means providing patients with appropriate serv‐
ices in a technically competent manner, with good communication, shared decision making
and cultural sensitivity.[4] Quality assurance can be defined as all those planned and sys‐
tematic actions necessary to provide adequate confidence that a product or service will satis‐
fy given requirements for quality.[5]
Donabedian originally coined the phrase quality of care.[6,7] He assessed quality of care by
looking at the triad of structures, processes and outcomes.
Structure attributes describe the physical and organizational settings in which care is pro‐
vided and evaluate whether these characteristics are conducive to the kind of care that can
be expected to improve health and to be acceptable to patients and the community. Evalua‐
tion of the adequacy of facilities, qualifications of medical staff, availability of equipment,
and organizational structure and operations of programs within the institution providing
care fall under the category of structure of care. Often-evaluated structural variables include
the demographic characteristics, training and experience of care providers and the environ‐
ment in which they work. Other structural variables of interest include access to specific
technologies, access to intensive care facilities and nurse-to-patient ratios. The most com‐
monly cited variable used as a surrogate for assessing surgical quality is hospital or physi‐
cian case volume.
Process of care describes the care the patient actually receives and evaluates the degree to
which interventions provided to patients correspond to what is known or believed to be
most effective in improving health. This includes: 1) the patient’s activity in seeking care
and carrying it out, and 2) the practitioner’s activities in making a diagnosis and recom‐
mending and implementing therapy. Whether care is effective can be judged according to
the evidence from good studies demonstrating a link between a particular process (ie., de‐
bulking surgery) and better outcomes (ie., prolonged survival). Process indicators are easily
measured in a timely fashion and can provide actionable feedback for quality improvement
initiatives. Other examples of process variables include guidelines for surgery and use of
care pathways. These variables are usually used in the context of quality assessment audits.
Outcomes are the actual changes in health and wellbeing obtained by patients and com‐
munities, and the degree to which the care provided is acceptable. In other words, outcome
is the effect of care on the health status of patients and populations. This may be improve‐
ment in patient knowledge, behaviour and satisfaction. Endpoints of interest in ovarian can‐
cer could include 30-day peri-operative mortality, overall survival, and quality of life.
Overall survival data takes a long time to mature and it reflects a culmination of many proc‐
esses and structures that have contributed to care. There is currently a strong focus on out‐
comes for patients with ovarian cancer, especially in the context of health care payers
obtaining high quality care for the health care dollars spent.[8]
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To demonstrate the concepts of structure, process and outcomes as ways to measure quality
of care in ovarian cancer, we will review population-based studies published over the last 10
years. We have restricted our scope to population-based studies because they provide out‐
comes for the whole population in a region and avoid biases inherent with single institution
studies (ie., related to socioeconomic status, race or comorbidities). As well, population-
based studies allow us the opportunity to identify where variations in care may lead to su‐
perior outcomes for the population. If these processes and/or structures are incorporated
into practice, they may lead to improved health outcomes.
3. Methods
A systematic search of the published English language literature from Jan 1, 2000 to Jun 29,
2012 was undertaken in order to present an unbiased view of the current population-based
literature in the field of quality of care. Several key articles were identified[9-11] and MeSH
terms from these references were used to create a search strategy for PubMed (Figure 1).
 
http:/ / www.ncbi.nlm.nih.gov/ entrez/ query.fcgi?CMD=search&term=(genital 
neoplasms, 
female[mh]+AND+(th[sh]+OR+su[sh]+OR+rt[sh]+OR+dt[sh]+OR+surgery[tiab]+OR+surgi
cal* [tiab]))+AND+(health planning[mh]+OR+”health care quality, access, and 
evaluation”[mh]+OR+”outcome and process assessment (health 
care)”[mh])+AND+(outcome*[ti]+OR+population*[ti]+OR+treatment 
outcome[majr])+AND+2000:2012[dp]+AND+english[la]&db=PubMed 
Figure 1. PubMed search strategy
The search yielded 1178 articles of which 172 were identified as potentially relevant by title
and abstract. To be included the article had to include population-based data collection re‐
lated to primary management of ovarian cancer. The article needed to report on structure or
processes of care in relation to outcomes. Articles were excluded if they were reporting on
screening for ovarian cancer, pre-cancerous or benign conditions; if they were focused solely
on quality of life, biologic therapies, biomarkers and personalized medicine, survivorship or
palliative care. We identified two systematic reviews of quality of care indicators.[12,13]
However, in both cases the authors did not restrict their study inclusion to population-based
reports, therefore these studies are not included in our analysis.
4. Results
The 30 population-based studies in this review represent findings from many high-income
countries, including Australia (1), Canada (3), USA (12), Austria (2), Finland (2), Germany
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(1), Netherlands (3), Norway (1), Switzerland (1), UK (3), and Japan (1). Twenty-five unique
studies report the impact of structure on outcomes, and 13 studies report the impact of vari‐
ous processes on outcomes. Included are 91,866 patients.
4.1. Outcomes
The 5-year overall survival rate is the indicator of most interest to clinicians caring for pa‐
tients with ovarian cancer. Other outcomes of interest include quality of life, patient satisfac‐
tion, and cost. However, when 5-year survival rates are so poor, surrogate outcomes,
including progression-free survival (PFS), can be used to reflect small changes in outcomes
that are important to patients and society. Changes in processes or structures that result in
improved surrogate outcomes should eventually be reflected in improved 5-year survival
rates. Surrogate outcomes in ovarian cancer include PFS and 30 or 60-day mortality.
4.2. Structure
In 25 unique population-based studies of quality of care in ovarian cancer, structural varia‐
bles evaluated include a hospital’s annual ovarian cancer surgical volume, physician annual
ovarian cancer surgical volume, hospital type (university affiliated vs community hospital),
and physician type (gynaecologic oncologist, general gynaecologist, or general surgeon).
These studies are listed in Table 1.
Studies evaluating hospital volume demonstrate hospitals with higher volumes of ovarian
cancer surgery per year are often associated with better long-term survival (Table 2). The
improvement in overall survival did not appear to be a reflection of peri-operative deaths,
because the 30 and 60-day mortality was not affected by hospital volume in the studies eval‐
uating those outcomes. The long-term survival advantage produced by high-volume hospi‐
tals is due to other differences in structures and processes of care in these institutions.
Studies evaluating physician volume did not demonstrate a uniform improvement in sur‐
vival when high-volume physicians operated on patients with ovarian cancer (Table 3).
Findings were inconclusive for both shorter and longer-term survival.
In just over half of the studies identified, hospitals classified as teaching facilities or univer‐
sity hospitals were associated with better short and long-term survival outcomes (Table 4).
Usually these specialized facilities provide access to physicians with expertise in complicat‐
ed gynaecologic oncology surgical procedures necessary for appropriate surgical manage‐
ment of ovarian cancer patients.
Studies evaluating physician specialization usually compare outcomes for patients operated
by gynaecologic oncologists versus general gynaecologists versus general surgeons. Opera‐
tion by a gynaecologic oncologist was associated in most studies with better outcomes in
terms of long-term survival (Table 5). It is likely that general surgeons are more likely to per‐
form emergency surgeries in advanced situations like bowel obstruction. However, the dif‐
ference in outcomes persisted even after adjusting for prognostic factors like the Charlson
comorbidity score.
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Stockton 2000[14] UK Retrospective database 989 Yes
Olaitan 2001[15] UK Prospective cohort 595 n/a
Carney 2002[16] USA Retrospective database 734 Yes
Elit 2002[17] Canada Retrospective database 3,815 Yes
Grossi 2002[18] Australia Retrospective database +
chart review
434 No
Kumpulainen 2002[19] Finland Retrospective database 3,851 Yes
Cress 2003[20] USA Retrospective database 1,088 n/a
Harlan 2003[21] USA Retrospective database 1,167 n/a
Ioka 2004[22] Japan Retrospective database 2,450 Yes
Diaz-Montez 2005[23] USA Retrospective database 2,417 n/a
Bailey 2006[24] UK Prospective cohort 361 No*
Earle 2006[25] USA Retrospective database 3,067 Yes
Elit 2006[11] Canada Retrospective database 2,502 No
Engelen 2006[26] Netherlands Retrospective database +
chart review
632 Yes
Goff 2006 and 2007[27,28] USA Retrospective database 10,432 n/a
Kumpulainen 2006 and
2009[29,30]
Finland Prospective cohort 275 Yes
Oberaigner 2006[31] Austria Retrospective database 911 Yes
Paulsen 2006[32] Norway Prospective registry 198 Yes
Schrag 2006[33] USA Retrospective database 2,952 Yes
Elit 2008[34] Canada Retrospective database 1,341 No
Bristow 2009[35] USA Retrospective database 1,894 Yes
Marth 2009[36] Austria Prospective cohort 1,948 Yes
Vernooij 2009[37] Netherlands Retrospective cohort 1,077 Yes
Mercado 2010[38] USA Retrospective cohort 31,897 Yes
Rochon 2011[39] Germany Prospective cohort 476 No
n/a: not applicable—these studies used surrogate outcomes, *the authors of this study reported it was underpowed
to find an association between structure and survival
Table 1. Studies reporting on structural variables in relation to outcomes for ovarian cancer
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Overall survival 7 3 10
DFS 1 0 1
30-day mortality 0 2 2
60-day mortality 0 1 1
DFS: disease-free survival
Table 2. Relationship between hospital volume and patient outcomes
Outcome Number of studies finding an
association between higher
volume and improved outcomes
Number of studies finding no
association between volume and
outcomes
Total
Survival 1 2 3
30-day mortality 1 2 3
60-day mortality 0 1 1
Table 3. Relationship between physician volume and patient outcomes
Outcomes Number of studies finding an
association between specialized
hospitals and improved outcomes




Overall survival 4 3 7
30-day mortality 1 1 2
Table 4. Relationship between hospital type and patient outcomes








Overall survival 6 3 9
30-day mortality 1 1 2
Table 5. Relationship between physician specialization and patient outcomes
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Several studies have reported a link between structural variables (hospital volume, physi‐
cian volume, hospital type and physician specialization) and outcomes. Population-based
studies  published  over  the  past  ten  years  identify  more  consistent  evidence  linking  in‐
creased hospital volume and increased physician specialization with long-term outcomes
than for  other  structural  variables.  Surgery by a  gynecologic  oncologist  appears  to  pro‐
vide superior outcomes in terms of long term survival. These studies pertain to the sur‐
gical  management  of  patients  with  ovarian  cancer.  The  single  study  looking  at
chemotherapy for  ovarian  cancer  patients  found no  association  between oncologist  vol‐
ume  of  chemotherapy  and  outcomes.[11]  Of  note,  no  study  demonstrated  worse  out‐
comes  with  higher  volumes  or  specialization  of  hospitals  or  physicians.  Some
jurisdictions  have  used  these  findings  to  implement  a  strategy  of  centralization  of  sur‐
gery  for  ovarian  cancer  in  an  effort  to  improve  quality  of  surgical  care  and  outcomes.
[40,41]
There are important limitations in this data. Not all studies were able to obtain individu‐
al data to allow adjustment for every important confounding variable which can impact
survival. The majority of these studies were retrospective or dependant on accurate data-
entry into databases.  It  is  possible some of the advantages observed for type or volume
of provider may be due to more diligent data-entry and documentation of patient demo‐
graphics,  stage and treatment received.  For example,  teaching hospitals  may have more
accurate  and  detailed  documentation  of  the  surgical  procedures  provided  to  patients
which may lead to an assumption that they provided more complete surgical care when
in fact  the  differences  were  in  documentation only.  The use  of  re-operation as  a  surro‐
gate  outcome  is  questionable  when  discussing  physician  type,  since  more  specialized
physicians are typically the ones making the decision to perform a second operation and
this decision is more likely to occur if the primary surgery was performed by a less spe‐
cialized surgeon.
4.3. Process
Evidence-based guidelines on the surgical care of women with ovarian cancer generally rec‐
ommend hysterectomy, bilateral salpingo-oophorectomy, and omentectomy. In early-stage
disease, staging should be performed, including cytology, peritoneal biopsies, and pelvic
and para-aortic lymphadenectomy. In late-stage disease, debulking should be performed,
including the removal of all macroscopic tumour. This sometimes requires the use of bowel
resection, splenectomy, diaphragmatic and peritoneal stripping.[42-44] Adjuvant or neoad‐
juvant chemotherapy with a combination of a platinum and a taxane agent has been the
standard of care for epithelial ovarian cancers over the past ten years.[45] Appropriate sur‐
gery and chemotherapy have a demonstrated impact on outcomes for ovarian cancer pa‐
tients and represent processes of care indicating quality.
Next we look at whether the processes evaluated in the literature are related to the four
structural variables reported, and whether these impact on survival.
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Number of studies finding an
association between higher volume
and improved processes




Adequate surgery 1 1 2
Optimal debulking 5 1 6
LND 3 0 3
Re-operation 2 0 2
Length of Stay 2 0 2
Complications 0 1 1
Adjuvant chemotherapy 1 0 1
LND: lymph node dissection
Table 6. Relationship between hospital volume and evidence-based processes
Higher hospital volumes of ovarian cancer surgery were associated with better compliance
to process steps in the optimal care of women with ovarian cancer (Table 6). These processes
included: surgery according to guidelines (optimal debulking, lymph node dissection) and
use of adjuvant chemotherapy.
Number of studies finding an
association between higher
volume and improved processes




LND 2 0 2
Optimal debulking 1 0 1
Length of stay 1 0 1
Re-operation 2 0 2
Adjuvant chemotherapy 1 0 1
Complications 0 1 1
Length of Stay 1 0 1
LND: lymph node dissection
Table 7. Relationship between physician volume and evidence-based processes
Surgery by physicians with higher volumes of ovarian cancer surgeries was also associated
with better compliance to process steps such as surgery according to guidelines and use of
adjuvant chemotherapy (Table 7).
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Number of studies finding an
association between specialized
hospitals and improved processes




Optimal debulking 3 0 3
LND 6 0 6
Re-operation 1 0 1
Adjuvant chemotherapy 5 0 5
LND: lymph node dissection
Table 8. Relationship between hospital type and evidence-based processes
Type of hospital (ie. teaching versus non-teaching, academic versus community) where sur‐
gery for ovarian cancer is performed was clearly associated with more appropriate surgery
and adjuvant chemotherapy in accordance with guidelines (Table 8).








Optimal debulking 6 0 6
LND 5 0 5
Re-operation 3 0 3
Adjuvant chemotherapy 4 0 4
LND: lymph node dissection
Table 9. Relationship between physician specialization and evidence-based processes
Physician specialization (ie., gynaecologic oncologist vs general gynaecologist vs general
surgeon) was also associated with appropriate surgery and adjuvant chemotherapy in ac‐
cordance with guidelines (Table 9).
In  summary,  13  population-based  studies  involving  22,255  patients  across  3  continents
linked processes of care to improved survival. The relationship of important processes of
care with survival is so clear that this work that has led to defining quality indicators for
the  treatment  of  ovarian  cancer  care.  In  Ontario,  Canada,  Gagliardi  and  colleagues[40]
used  the  Delphi  technique  to  define  quality  indicators.  More  recently,  Verleye  and  the
EORTC has defined and set surgical benchmarks for quality care in ovarian cancer (Table
11., Appendix).[46]
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Study Country Data Source Number of
patients
Which process variables affected
survival?
Surgery Chemo
Bailey 2006[24] UK Prospective cohort 361 X
Chan 2008[47] USA Retrospective
database
8,372 X
Elit 2006[11] Canada Retrospective
database
2,502 X X
Elit 2008[34] Canada Retrospective
database
1,341 X X




Fairfield 2010[48] USA Retrospective
database
4,589 X









Maas 2005[50] Netherlands Retrospective
database
1,116 X X
Marth 2009[36] Austria Prospective cohort 1,948 X











Table 10. Studies reporting on process variables in relation to outcomes in ovarian cancer
5. Processes or structures of care that require further evaluation
There are many processes considered by experts to be important in the care of women with
ovarian cancer. These process variables have face validity but have not yet been clearly eval‐
uated for their impact on outcomes in ovarian cancer. Additionally, the organizational struc‐
ture for care provision is a complex construct; it is unclear what components contribute
most positively to outcomes. We wish to focus on three variables that may or may not be
related to survival but may impact treatment and decision making.
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5.1. Pathology assessment
When making a diagnosis of ovarian cancer, the histology may be assessed by a pathologist,
a pathologist with interest and experience in gynaecologic malignancies, or a subspecialist
gynaecologic pathologist. Heatley[53] defines a pathologist as someone who has completed
training and passed the appropriate examinations. A pathologist with a special interest (PSI)
is a general pathologist who takes the lead in a subspecialty area within their department
such as gynaecological pathology, attending meetings of specialist societies, participating in
the appropriate subspecialist external quality assurance scheme, providing specialist opin‐
ions for colleagues in the department, and on occasion, neighbouring departments. A sub‐
specialist pathologist is a pathologist with a special interest but who now, possibly after a
period working as a general pathologist, devotes all or the vast majority of their time to one
area of practice.[53] Subspecialisation leads to standardisation of pathology reports and im‐
proved communication of findings, participation in multidisciplinary tumour board meet‐
ings, enhanced knowledge and standards, decreased turnaround times, quality assurance of
diagnoses, improved quality of resident training, ability to distinguish appropriate variation
from the standard of care, and advancement of academic knowledge through participation
in research.[54]
In gynaecologic oncology, there are several studies reporting up to a 16.9% discrepancy with
the referral diagnosis when a PSI or a subspecialist gynaecologic pathologist provides a re‐
view of the original pathology.[55] In 4.7% -12% of cases there is a change in diagnosis
which has a major therapeutic or prognostic implication.[55-58] Although these findings
were from studies including all gynaecologic malignancies rather than ovarian cancer spe‐
cifically, they demonstrate subspecialist pathology review has an important role to play in
the care of patients with ovarian cancer. Verleye and colleagues[59] found that pathology re‐
ports for ovarian cancer surgery originating from high-volume centres and academic hospi‐
tals are of higher quality than those originating from lower volume or non-academic centres.
The availability of subspecialist gynaecologic pathologists may be one structural aspect of
care in these centres leading to better outcomes. The impact of expert pathology review in
ovarian cancer needs to be evaluated as a process step that could impact survival.
5.2. Multidisciplinary care
Multidisciplinary care is an integrated team-based approach to cancer care where medical
and allied health care professionals consider all relevant treatment options and collabora‐
tively develop an individual treatment and care plan for each patient. Evidence in oncolo‐
gy  suggests  that  multidisciplinary  care  leads  to  improved  survival  and  quality  of  life,
satisfaction with treatment, and mental well-being of clinicians.[60] An important compo‐
nent  of  multidisciplinary care is  availability of  regularly scheduled tumour board meet‐
ings[61] with participation of gynaecologic oncologists, pathologists, radiologists, radiation
and medical oncologists, and allied health professionals with a special interest in care of
gynaecologic  oncology  patients.  Tumour  board  conferencing  in  Auckland City  Hospital
from 2005-2006 led to a 5.9% rate of major changes in patient management.[62] This re‐
sulted from radiologic review (major discrepancy rate 1.4%) and pathology review (major
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discrepancy  rate  of  4.5%)  which  led  to  identification  of  major  diagnostic  discrepancies.
However, they could not quantify how the changes in diagnosis and management might
impact patient outcomes. Santoso did a comparison of the initial gynecologic cancer diag‐
nosis and management plan to the diagnosis and management plan after discussion at a
multidisciplinary tumor board meeting. They showed that 6.9% of cases discussed at tu‐
mor  board  had  changes  made  to  the  diagnosis  or  plan,  and  in  5%  there  were  major
changes in treatment.[63] The most convincing research suggesting care by a multidiscipli‐
nary team is a process that improves outcomes was published by Junor and colleagues us‐
ing  population-based data  from Scotland.  In  a  retrospective  analysis  of  all  533  cases  of
ovarian cancer diagnosed in Scotland in 1987, referral to a multidisciplinary team was one
of five factors significantly associated with improved 5 yr survival after adjusting for pa‐
tient and disease characteristics (hazard ratio 0.60, p<0.001).[64]
5.3. Institutional participation in clinical trials
Several studies have identified clinical trial participation as an institutional marker of quali‐
ty care. In 1994, Stiller published a review of several cancer disease sites and found that
across disease sites, patients treated as part of a clinical trial had better outcomes.[65] du
Bois and colleagues evaluated outcomes in a population-based cohort of patients diagnosed
with ovarian cancer in Germany in 2001.[52] After adjusting for disease stage, patients treat‐
ed in an institution participating in multi-centre clinical trials had improved overall survival
(35 months vs 25 months for patients with stage III-IV ovarian cancer treated at participating
vs non-participating hospitals).[39,52] Notably, patients treated in participating hospitals
had better outcomes even if they were not themselves participating in a trial. Patients treat‐
ed in hospitals participating in trials were more likely to receive care in accordance with
clinical practice guidelines including staging, debulking and combination chemotherapy
where appropriate.[39] Trial participation at an individual patient level may indicate good
performance status that can, in and of itself, lead to better outcomes. However, it appears all
patients treated at hospitals participating in trials may benefit from improved outcomes.
This is likely due to differences in processes of care at these institutions.
6. What does all this mean?
When geographic variation in outcomes exist at a population level, there are opportunities
to assess whether changes in structures or processes of care could improve outcomes. There
have been several strategies to improve outcome. One is to standardize care using evidence-
based guidelines and techniques to optimize processes like a structured care path, whether
in a paper chart or as part of an electronic medical record. Another approach to try to im‐
prove outcomes at a population level has been to centralize care. In some situations where
care requires an experienced surgical team and highly developed perio-operative care, such
as for the surgical management of pancreatic cancer, there is evidence that centralization of
care to high-volume centres decreases 30-mortality.[66] However, not all reports are consis‐
tent with this finding.[67] Another strategy to improve outcomes is to focus on improving
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processes by the involvement of highly regarded opinion leaders providing education. More
consistent improvement in processes of care has been noted using the audit and feedback
system.[68] These approaches have been variously referred to as quality assessment, quality
management quality improvement and knowledge translation. In this paper, we refer to
quality assessment as the audit process whereby performance is measured and compared
with a reference standard. Quality improvement includes the steps taken to actively change
practice to improve adherence to processes and to improve outcomes.
7. Quality assurance and monitoring
Quality assurance and monitoring of outcomes is essential to allow for quality improvement
initiatives. Regions, hospitals, and care providers must understand which outcomes are not
reaching a targeted standard in order to identify structures and processes which may im‐
prove outcomes. Initiatives such as the International Cancer Benchmarking Partnership[69]
have used population-based registry data to identify significant discrepancies in survival for
women with ovarian cancer based on geographic location. Striking differences were ob‐
served, with women in Australia and Canada having significantly longer survival than
women in the UK and Denmark after adjusting for stage.[70]
Measuring the quality of surgical procedures has lagged behind quality-assurance initiatives
in other areas because of the difficulty in identifying parameters to evaluate.[71] Early stud‐
ies suggested operative morbidity and mortality, adequacy of resection, local recurrence and
survival as parameters to measure surgical quality.[71] However several of these factors are
also highly influenced by the use of appropriate adjuvant therapy. Several programs have
now begun systematically tracking outcomes for surgical oncology patients in an effort to
identify areas where quality improvement measures should be implemented.
One such program is the American College of Surgeons (ACS) National Surgical Quality
Improvement Program (NSQIP).[72] This is a nationally validated, multi-specialty, risk-ad‐
justed 30-day outcomes measurement  program which originated in the Veterans Health
Administration in 1991.  Since 2004,  NSQIP has been expanding and now includes more
than 400 hospitals in the US, Canada, Lebanon and the UAE. The aim of the program is to
provide institutions and surgeons with 30-day outcomes which can be used to compare
performance to other institutions.  Risk adjustment incorporates pre-operative comorbidi‐
ties and intra-operative risk factors using hierarchical modelling. Twice per year, institu‐
tions  are  given  a  report  with  their  risk-adjusted  outcomes  in  the  form  of  odds  ratios,
which can be used for  bench-marking.  After  implementation of  NSQIP in 10 Tennessee
hospitals,  significantly  fewer  surgical  site  infections,  failed  grafts  and flaps,  episodes  of
acute  renal  failure,  and prolonged ventilation  of  more  than 48  hours  was  achieved.[73]
The ACS evaluated outcomes across all  participating institutions from 2005 to 2007 and
found 66% of  hospitals  showed improvement  in  30-day mortality  and 82% of  hospitals
achieved a reduction in complications after enrollment in the NSQIP program.[74] These
improvements also led to significant cost savings. The remarkable success of this program
will likely lead to further expansion.




Quality improvement naturally follows from quality assessment. Review of performance in
terms of adherence to best-practices (processes of care) in a methodologically rigorous and
transparent manner (quality assessment) can lead to improvement in outcomes if interven‐
tions are undertaken to improve areas of weakness in performance. Interventions based on
quality assurance data attempt to improve processes of care in order to improve outcomes.
A framework for quality improvement could include the following steps:[75]
1. Debate and select values and goals that will inform the effort
2. Select a clinical area requiring improvement
3. Select team members
4. Select relevant quality markers for improvement
5. Collect data for selected markers
6. Select and operationalize interventions to achieve improvements in markers
7. Re-evaluate, modify and repeat the steps
The American Society of Clinical Oncology (ASCO) initiated the Quality Oncology Practice
Initiative (QOPI)[76] for US-based Hematology-Oncology practices in order to improve
quality of cancer care by using measurement and feedback and by providing improvement
tools. Processes of care indicative of quality were identified by a group of oncologists using
consensus and clinical practice guidelines.[77] QOPI provides individual care providers
with quality of care benchmarking information twice per year, allowing clinicians to make
improvements within their own practices. Implementation of QOPI and sharing results with
physicians at one academic oncology centre in the US led to significant improvements in
several areas of quality.[78] Although this program is only available to medical oncology
practices in the US, it serves as a good example of how measurement and feedback can lead
to improvement in quality of care.
A quality management program was implemented in one German academic oncology cen‐
tre in 2001 with the aim of improving the quality of surgery provided to patients with ovari‐
an cancer.[79] The components of the quality management system included establishment of
a prospective tumour registry, creation and training of dedicated surgical teams operating
on patients with advanced ovarian cancer, inter-disciplinary surgical care, intra-operative
second opinion by another gynecologic oncologist if the first surgeon did not believe de‐
bulking to microscopic residual disease was attainable, interdisciplinary management of
complications, and quality conferences including assessment and benchmarking of morbidi‐
ty and survival outcomes. This effort, along with a significant increase in the volume of
ovarian cancer surgery performed at this centre over time, led to a significant improvement
in processes and outcomes. Debulking to microscopic residual disease increased from 33%
in 1997-2000, and 47% in 2001-2003, to 62% in 2004-2008. This led to median survival of 26
months for patients treated in 1997-2000, 37 months in 2000-2003 and to 45 months in
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2004-2008 and 5-year survival in 24%, 34% and 36% of patients in the three time periods.
Changes in both structures and processes of care were achieved using this quality manage‐
ment system, leading to improved survival for patients.[79]
A quality improvement program for the surgical care of patients with advanced ovarian
cancer was implemented at the Mayo Clinic using an audit and feedback approach, with the
aim of increasing the proportion of patients debulked to microscopic residual disease.[44] A
surgical complexity score was developed to categorize the aggressiveness of the surgical ap‐
proach.[80] The quality improvement program consisted of weekly conferences where pa‐
tient outcomes and treatment approaches were discussed, confidential benchmarking
allowing individual surgeons to see their rates of complete surgical debulking in compari‐
son to peers, teaching fellows and staff how to perform techniques needed for complete de‐
bulking, and intra-operative mentoring of staff and fellows by surgeons experienced in
advanced procedures. After the quality improvement program was implemented, rates of
debulking to microscopic disease increased from 31% to 43%.
9. Knowledge translation
Knowledge translation is the science of moving knowledge into action.[81] Several studies
across various disciplines in medicine have demonstrated many patients do not receive care
known to improve outcomes.[81,82] One of the first groups to show this in ovarian cancer
was Munstedt and colleagues who found a large proportion of patients treated in Hesse,
Germany between 1997 and 2001 did not receive care recommended in national guidelines.
[83] Knowledge translation aims to bridge the gap between what is known from research,
and implementation of this knowledge in an effort to improve outcomes for patients and ef‐
ficiency for the health care system.[81]
Knowledge translation has been described as a cycle, where a clinical problem is identified
(possibly by quality assurance or monitoring efforts), processes of care are identified from
research to address the problem, these processes are adapted to the local context and any
barriers to implementation are identified and addressed, and the new processes are imple‐
mented. After implementation, adherence to the process is monitored, and final patient out‐
comes are evaluated.[81] Evaluation of outcomes and monitoring of processes may then
identify additional clinical problems. If no evidence-based solution to the problem is identi‐
fied, this leads to a need for additional research. In this way, new research informs clinical
practice, and problems from clinical practice help to identify research priorities.[82]
A major focus of knowledge translation research is finding ways to change clinician and pa‐
tient behaviour given the results of research. Simply publishing new findings in peer-re‐
viewed journals, a method termed ‘diffusion’, is not adequate for wide-spread adoption of
new processes.[84] Other methods that have been investigated include audit and feedback,
[85] educational outreach by local opinion leaders,[86] and clinical decision support and re‐
minder systems which can be integrated into computer-based patient-care platforms.[87]
Audit and feedback, such as the ACS NSQIP or ASCO QOPI programs, are one of the most
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effective methods for behaviour change in clinicians.[68,88] An excellent overview of these
methods has been published by Brouwers and colleagues, who performed a review of sys‐
tematic reviews on knowledge translation interventions used in cancer control.[68] The sci‐
ence of knowledge translation is relatively new. As research methods continue to improve,
strategies are expected to be refined.
Figure 2. Flow diagram for study selection
10. Conclusion
Women with ovarian cancer should be treated in institutions providing high quality care.
Quality of care can be evaluated by examining the processes and structures of care leading
to improved outcomes such as survival and quality of life.
In the US, there is a trend to link reimbursement for hospitals and care providers to clinical
outcomes in an effort to improve quality of care.[72] Because of financial pressures in the
health care system, this trend is expected to continue, since improvement in several metrics
used to identify quality surgical care (such as decreased surgical site infections) can save a
significant amount of money. Whether health systems are achieving value for money can
only be assessed if performance is measured in a systematic way. Tracking outcomes with
the use of population-based registries is an essential component of quality assurance, which
allows for comparison of outcomes across jurisdictions.[71] Identifying variations in out‐
comes can then trigger specific quality improvement initiatives. Knowledge translation is
Ovarian Cancer - A Clinical and Translational Update18
the science of moving knowledge into action, and encompasses both quality assurance and
quality improvement. The concepts underlying quality of care are essential information for
health care providers caring for women with ovarian cancer given the current global focus
on outcomes and value for money in health care systems.
Appendix
Early-stage epithelial ovarian cancer -Percent of patients with a suspicious ovarian mass undergoing staging
laparotomy within 1 month after decision to treat or documented clinical or
patient-related reason for delay
-Percent of performed staging laparotomies for an ovarian mass suspected to
be malignant performed through a vertical incision
Percent of performed staging laparotomies in which all of the following
procedures are included: total hysterectomy, bilateral salpingo-oophorectomy,
cytology of the peritoneal cavity, infracolic omentectomy, random peritoneal
biopsies and systematic pelvic and para-aortic lymphadenectomy if medium or
high risk features
Percent of surgery reports with documented presence or absence of cyst
rupture before or during surgery
Percent of surgery reports with documented presence or absence of dense
adhesions, percent of dense adhesions biopsied
Primary debulking surgery in
advanced-stage epithelial ovarian
cancer
Percent of patients with advanced-stage ovarian cancer undergoing debulking
laparotomy within 31 days after decision to treat or documented clinical or
patient-related reason for delay
Percent of patients undergoing debulking surgery with the spread of disease
fully assessed for operability at the start of study and initial findings
documented in the operation notes
Percent of debulking operations including a hysterectomy, bilateral salpingo-
oophorectomy and infracolic omentectomy when the surgeon considers
optimal debulking feasible
Percent of debulking operations for advanced ovarian cancer at the end of
which complete cytoreduction, defined as no macroscopic residual disease at
the end of the operation, was achieved
Percent of debulking operations including a pelvic and para-aortic
lymphadenectomy when otherwise complete debulking has been achieved
percent of debulking operations for which the size and location of residual
disease at the end of the operation is documented in the operation notes
Table 11. EORTC benchmarks for quality surgical care in ovarian cancer[46]
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